IP Library Granted Patent US 8,871,279
Granted Patent B2
US 8,871,279 · App. 12/997,513 · Granted Oct 28, 2014

Use of the combination of PHY906 and a tyrosine kinase inhibitor as a cancer treatment regimen

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,871,279
App. No.
12/997,513
Granted
Oct 28, 2014
Kind
B2
Abstract

This invention provides herbal compositions useful for increasing the therapeutic index of chemotherapeutic compounds. This invention also provides methods useful for improving the quality of life of an individual undergoing chemotherapy. Furthermore, this invention improves the treatment of cancer by administering the herbal composition PHY906 in combination with one or more chemotherapeutic compounds to a mammal undergoing such chemotherapy.

Claims (30)

1. A method of treating gastrointestinal stromal tumors or renal cell carcinoma in a mammal comprising administering a therapeutically effective amount of

i) an herbal preparation consisting essentially of Scutellaria baicalensis, Glycyrrhiza uralensis, Ziziphus jujuba , and Paeonia lactiflora ; and

ii) a chemotherapeutic formulation comprising sunitinib or the malate salt of sunitinib.

2. The method of claim 1 , wherein the herbal preparation and the chemotherapeutic formulation are administered at separate times.

3. The method of claim 1 , wherein the herbal preparation and chemotherapeutic formulation are administered via oral route.

4. The method of claim 1 , wherein the herbal preparation consists of Scutellaria baicalensis, Glycyrrhiza uralensis, Ziziphus jujuba, Paeonia lactiflora , and one or more pharmaceutically acceptable carriers.

5. The method of claim 1 , wherein the chemotherapeutic formulation comprises sunitinib or the malate salt of sunitinib.

6. The method of claim 1 , wherein the herbal preparation is administered before the administration of the chemotherapeutic formulation.

7. The method of claim 1 , wherein the herbal preparation is administered after the administration of the chemotherapeutic formulation.

8. The method of claim 1 , wherein the herbal preparation is administered concurrently with the administration of the chemotherapeutic formulation.

9. A method of relieving side effects of sunitinib or the malate salt of sunitinib in a mammal comprising administering a therapeutically effective amount of

i) an herbal preparation consisting essentially of Scutellaria baicalensis, Glycyrrhiza uralensis, Ziziphus jujuba , and Paeonia lactiflora ; and

ii) a chemotherapeutic formulation comprising sunitinib or the malate salt of sunitinib.

10. The method of claim 9 , wherein the herbal preparation and the chemotherapeutic formulation are administered at separate times.

11. The method of claim 9 , wherein the herbal preparation and chemotherapeutic formulation are administered via oral route.

12. The method of claim 9 , wherein the herbal preparation consists of Scutellaria baicalensis, Glycyrrhiza uralensis, Ziziphus jujuba, Paeonia lactiflora , and one or more pharmaceutically acceptable carriers.

13. The method of claim 9 , wherein the chemotherapeutic formulation comprises sunitinib or the malate salt of sunitinib.

14. The method of claim 9 , wherein the herbal preparation is administered before the administration of the chemotherapeutic formulation.

15. The method of claim 9 , wherein the herbal preparation is administered after the administration of the chemotherapeutic formulation.

16. The method of claim 9 , wherein the herbal preparation is administered concurrently with the administration of the chemotherapeutic formulation.

17. A method of enhancing anticancer activity of sunitinib or the malate salt of sunitinib in a mammal comprising administering a therapeutically effective amount of

i) an herbal preparation consisting essentially of Scutellaria baicalensis, Glycyrrhiza uralensis, Ziziphus jujuba , and Paeonia lactiflora ; and

ii) a chemotherapeutic formulation comprising sunitinib or the malate salt of sunitinib.

18. The method of claim 17 , wherein the herbal preparation and the chemotherapeutic formulation are administered at separate times.

19. The method of claim 17 , wherein the herbal preparation and chemotherapeutic formulation are administered via oral route.

20. The method of claim 17 , wherein the herbal preparation consists of Scutellaria baicalensis, Glycyrrhiza uralensis, Ziziphus jujuba, Paeonia lactiflora , and one or more pharmaceutically acceptable carriers.

21. The method of claim 17 , wherein the chemotherapeutic formulation comprises sunitinib or the malate salt of sunitinib.

22. The method of claim 17 , wherein the herbal preparation is administered before the administration of the chemotherapeutic formulation.

23. The method of claim 17 , wherein the herbal preparation is administered after the administration of the chemotherapeutic formulation.

24. The method of claim 17 , wherein the herbal preparation is administered concurrently with the administration of the chemotherapeutic formulation.

Assignments (10)
RELEASE OF SECURITY INTEREST Recorded Oct 29, 2021
From: MACQUARIE US TRADING LLC
To: KADMON CORPORATION, LLC
Reel/Frame 057973/0751 →
TERMINATION OF PATENT AND TRADEMARK SECURITY AGREEMENT Recorded Nov 25, 2019
From: PERCEPTIVE CREDIT OPPORTUNITIES FUND, LP
To: KADMON CORPORATION, LLC
Reel/Frame 051106/0677 →
SECURITY INTEREST Recorded Sep 8, 2015
From: KADMON CORPORATION, LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 036573/0001 →
RELEASE OF SECURITY INTEREST Recorded Sep 1, 2015
From: MACQUARIE US TRADING LLC
To: KADMON CORPORATION, LLC
Reel/Frame 036518/0862 →
SECURITY INTEREST Recorded Aug 31, 2015
From: KADMON CORPORATION, LLC
To: PERCEPTIVE CREDIT OPPORTUNITIES FUND, LP
Reel/Frame 036515/0084 →
SECURITY AGREEMENT Recorded Jun 25, 2013
From: KADMON CORPORATION LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 030679/0212 →
SECURITY AGREEMENT Recorded Jun 25, 2013
From: KADMON CORPORATION LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 030679/0116 →
SECURITY AGREEMENT Recorded Nov 23, 2011
From: KADMON CORPORATION, LLC
To: CORTLAND CAPITAL MARKET SERVICES LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 027278/0787 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2011
From: CHENG, YUNG-CHI; JIANG, ZAOLI
To: YALE UNIVERSITY
Reel/Frame 027064/0962 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 14, 2011
From: LIU, SHWU-HUEY; TILTON, ROBERT
To: YALE UNIVERSITY
Reel/Frame 027064/0407 →